Title
Category
Credits
Event date
Cost
- Disease management
- 1.25 ACPE - Pharmacists
- 1.25 ACPE - Pharmacy Technicians
- 1.25 AMA - Physicians
- 1.25 ANCC - Nurses
- 1.25 APA - Psychologists
- 1.25 Attendance - General Attendance
- 1.25 ASWB - Social Workers
$0.00
Gene therapy technologies are revolutionizing treatment for genetic diseases. This session explores the science, clinical applications, and patient perspectives, with a focus on sickle cell disease and emerging technologies like CRISPR.
- Disease management
- 1.25 ACPE - Pharmacists
- 1.25 ACPE - Pharmacy Technicians
- 1.25 AMA - Physicians
- 1.25 ANCC - Nurses
- 1.25 APA - Psychologists
- 1.25 Attendance - General Attendance
- 1.25 ASWB - Social Workers
$0.00
This session explores the latest updates in the diagnosis and management of chronic obstructive pulmonary disease (COPD) as outlined in the 2025 GOLD Report. Early case finding, refined spirometry protocols and novel therapeutic options are discussed, along with the importance of pre-bronchodilator spirometry, strategies for early detection in at-risk populations, and the integration of new treatments into updated treatment algorithms.
- Disease management
- 1.25 ACPE - Pharmacists
- 1.25 ACPE - Pharmacy Technicians
- 1.25 AMA - Physicians
- 1.25 ANCC - Nurses
- 1.25 APA - Psychologists
- 1.25 Attendance - General Attendance
- 1.25 ASWB - Social Workers
$0.00
Heart failure remains a leading cause of hospitalization and mortality. This session focuses on recognizing early signs, diagnostic tools, and evidence-based strategies to optimize care, improve patient quality of life, and reduce readmissions.
- Disease management
- Vision
- 1.00 AMA - Physicians
- 1.00 Attendance - General Attendance
- 1.00 COPE - Optometrists
$0.00
This activity will provide a current update to participants’ comprehensive knowledge and understanding of various contact lens options for patients with common diagnoses requiring medically necessary contact lenses. This session will delve into the tool chest of contact lens solutions, including standard rigid gas permeable (RGP) lens designs, reverse geometry RGPs, hybrids and scleral lenses. Participants will explore the anatomy of contact lenses, specific designs and applications for conditions such as keratoconus and irregular corneas. The activity will also cover the advantages and considerations associated with each lens type, patient experiences and advancements in scleral lens designs.
- Disease management
- Wellness
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 ASWB - Social Workers
$0.00
GLP-1 receptor agonists have reshaped the landscape of obesity and type 2 diabetes management, offering benefits beyond glycemic control. This session explores their mechanisms, clinical applications, and emerging evidence on their implications for broader metabolic care and in the treatment of obesity-related conditions such as obstructive sleep apnea.
- Disease management
- 0.50 ACPE - Pharmacists
- 0.50 ACPE - Pharmacy Technicians
- 0.50 AMA - Physicians
- 0.50 ANCC - Nurses
- 0.50 APA - Psychologists
- 0.50 Attendance - General Attendance
- 0.50 CDR - Dietitians
- 0.50 ASWB - Social Workers
$0.00
Essentials of Oncology and Transplant Management is designed for all who are interested in learning best practices for optimal patient and/or benefit management in the fields of transplant medicine and oncology.
- Disease management
- 1.00 AAPC - Coders
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 Attendance - General Attendance
03/31/2026
$0.00
This live webcast will provide primary care clinicians with a practical, guideline aligned approach to improving COPD care, including earlier and more accurate diagnosis through consistent spirometry use and optimization of inhaled therapy. It will highlight targeted and appropriate use of inhaled corticosteroids (ICS), including how to identify patients unlikely to benefit and how to minimize ICS-related risks. The activity will also review standardized strategies for managing exacerbations, emphasize high value non pharmacologic interventions—particularly pulmonary rehabilitation, inhaler technique education, and adherence support—and outline coordinated, cost-conscious care pathways, including appropriate pulmonology referral and careful selection of advanced therapies such as biologics for those patients most likely to benefit.

Facebook
X
LinkedIn
Forward